已核实 DOI PubMed 相关产品: 7

Immunostimulatory lipogel implant enhances cancer immunotherapy

Journal 2026 · IF 37.5 · 发表于 2026 年 7 月 23 日
作者: Zhang Ying,Wang Enlai,Li Shiyang,Yao Yufan,Shao Quanlin,Wang Yanfang,He Yingjiao,Liu Mingqi,Jin Xiang,Gu Zhen,Mo Ran
阅读全文 在 PubMed 查看

摘要

Cancer stem-like cells contribute to innate tumour immunoresistance and an immunosuppressive tumour microenvironment, leading to poor responses to immune checkpoint inhibitors. Chemotherapeutic agents can elicit tumour immunogenicity by inducing immunogenic cell death to reinforce the therapeutic efficacies of immune checkpoint inhibitors, but suffer from inefficient immunogenic cell death activation in highly resistant cancer stem-like cells. Here we report an immunostimulatory lyotropic liquid-crystal-based lipogel for localized co-delivery of all- trans retinoic acid, a differentiation-inducing drug, and doxorubicin, an immunogenic-cell-death-inducing chemotherapeutic agent with distinct release kinetics. The lipogel is tailored to release the combinatorial drugs in a differential and sustained manner, which fulfils the requirement for enhanced drug synergism in promoting the immunogenic cell death of cancer stem-like cells. Local implantation of the immunostimulatory lipogel elicits an antitumour immune response that is further augmented by an immune checkpoint inhibitor to suppress tumour growth and metastasis, as well as to prevent post-surgical recurrence in murine models of high-stemness tumours.

本研究中使用的阿拉丁产品

7 款产品在本文中被引用